Sidr Honey a compendium

Educational notes on chemistry and pollen analysis. Not medical advice. How we cite

← Back to Study Library
in-vitroPublished 2025DOI: 10.1186/s43094-025-00774-x

Hadhramaut Sidr Extract vs. Multidrug-Resistant Biofilms

Antimicrobial and antioxidant potential of Yemeni Sidr honey against multidrug-resistant pathogens — in vitro and in silico studies

Alhadrami HA, Sayed AM, Hassan HM, Rateb ME, Taher MA — Future Journal of Pharmaceutical Sciences (2025)

Key Metric
68.2%
P. aeruginosa biofilm inhibition in vitro
Sample & Study Design

In vitro biofilm and growth-inhibition assays across eight resistant bacterial and fungal strains using 200 µg/mL honey extracts, paired with computational docking.

Sample tested: Hadhramaut Governorate, Yemen (November 2021 harvest)

Measured Observation

Hadhramaut Sidr extract inhibited Pseudomonas aeruginosa biofilm formation by 68.2% (vs. 55.2% for imipenem) and Candida albicans by 62.6% (vs. 56.1% for fluconazole), with 94.2% growth inhibition on Staphylococcus aureus.

Methodology Notes

  • Researchers prepared concentrated ethanol extracts from a single Hadhramaut Sidr collection rather than testing raw whole honey directly.
  • In silico docking flagged chrysin, ellagic acid, and caffeic acid as candidate phenolic compounds.

Methodological Limitations & Caveats

  • Concentrated ethanol extracts (200 µg/mL) do not represent dietary honey intake.
  • Conducted strictly in vitro and in silico with no animal or human clinical testing.
  • Based on one collection sample; harvest-to-harvest variance was not measured.
View Original Paper / CitationSummary for educational reference only; not medical advice.